Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Xspray Pharma AB

Xspray Pharma Submits XS003 to the FDA – The Company’s Second Product Candidate from the HyNap Platform
From Xspray Pharma AB
Via Business Wire
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission
From Xspray Pharma AB
Via Business Wire
Xspray Pharma’s XS003 Study Shows Matching Bioavailability to Tasigna at More than a 50% Lower Dose
From Xspray Pharma AB
Via Business Wire
Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib
From Xspray Pharma AB
Via Business Wire
Xspray Pharma’s XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA® at Reduced Dosage
From Xspray Pharma AB
Via Business Wire
DASYNOC™ Uptake into the Blood Remains Consistent When Taken with Omeprazole, Whereas SPRYCEL® Uptake is Significantly More Impaired than Previously Understood
From Xspray Pharma AB
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.